Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed non-small cell lung cancer~  * Stage IIIB or IV or recurrent disease~* Measurable or evaluable indicator lesions~* Must have smoked ≥ 100 cigarettes in his/her lifetime~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* WBC ≥ 4,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min~* Bilirubin ≤ 1.0 mg/dL~* AST ≤ 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 1 week after completion of study treatment~* No gastrointestinal tract disease or inability to take oral medication~* No prior malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other active medical problems, including severe infection, unstable angina, or myocardial infarction within the past 6 months~* No poorly controlled hypertension or severe malnutrition~* No New York Heart Association class III or IV congestive heart failure or serious cardiac arrhythmia requiring medication except chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia)~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior radiotherapy to major bone marrow-containing sites~* No prior chemotherapy for advanced non-small cell lung cancer~* No prior agents directed at the epidermal growth factor receptor (EGFR)/HER axis (e.g., gefitinib, cetuximab, or trastuzumab \[Herceptin®\])~* No prior surgical procedure resulting in abnormal absorption of oral medications~* No concurrent surgical resection, palliative radiotherapy, or hormonal therapy~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- 150 PRE (Type: EXPERIMENTAL): Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2
- 1,500 PRE (Type: EXPERIMENTAL): Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2
- 1,500 POST (Type: EXPERIMENTAL): Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).